CA2476765A1 - Methods of preventing or treating brain ischemia or brain injury - Google Patents
Methods of preventing or treating brain ischemia or brain injury Download PDFInfo
- Publication number
- CA2476765A1 CA2476765A1 CA002476765A CA2476765A CA2476765A1 CA 2476765 A1 CA2476765 A1 CA 2476765A1 CA 002476765 A CA002476765 A CA 002476765A CA 2476765 A CA2476765 A CA 2476765A CA 2476765 A1 CA2476765 A1 CA 2476765A1
- Authority
- CA
- Canada
- Prior art keywords
- taipoxin
- gamma
- narp
- species
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35906102P | 2002-02-21 | 2002-02-21 | |
US60/359,061 | 2002-02-21 | ||
PCT/US2003/005090 WO2003072543A2 (en) | 2002-02-21 | 2003-02-20 | Methods of preventing or treating brain ischemia or brain injury |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2476765A1 true CA2476765A1 (en) | 2003-09-04 |
Family
ID=27766036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002476765A Abandoned CA2476765A1 (en) | 2002-02-21 | 2003-02-20 | Methods of preventing or treating brain ischemia or brain injury |
Country Status (7)
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003223184A1 (en) * | 2002-02-21 | 2003-09-09 | Fujisawa Pharmaceutical Co., Ltd. | Methods of preventing or treating brain ischemia or brain injury |
CN1605336A (zh) | 2003-10-10 | 2005-04-13 | 中国医学科学院药物研究所 | 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用 |
EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
AU2014224599B2 (en) | 2013-03-08 | 2018-11-08 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4341762A (en) * | 1981-04-07 | 1982-07-27 | Haast William E | Use of snake venoms for treatment of neurological and related disorders |
US6316602B1 (en) * | 1994-05-03 | 2001-11-13 | Binie V. Lipps | Beta taipoxin as a cell growth factor and method |
US5767252A (en) | 1996-04-08 | 1998-06-16 | The Johns Hopkins University School Of Medicine | Neuronal cell growth factor, Narp |
US6124610A (en) * | 1998-06-26 | 2000-09-26 | Advanced Micro Devices, Inc. | Isotropically etching sidewall spacers to be used for both an NMOS source/drain implant and a PMOS LDD implant |
WO2000075661A1 (en) | 1999-06-09 | 2000-12-14 | The Johns Hopkins University School Of Medicine | Method for identifying compounds which affect synaptogenesis |
EP1101820A1 (en) | 1999-11-15 | 2001-05-23 | MERCK PATENT GmbH | Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
WO2001063293A2 (en) | 2000-02-24 | 2001-08-30 | Oxford Glycosciences (Uk) Ltd. | Diagnosis and treatment of schizophrenia |
AU2003223184A1 (en) * | 2002-02-21 | 2003-09-09 | Fujisawa Pharmaceutical Co., Ltd. | Methods of preventing or treating brain ischemia or brain injury |
-
2003
- 2003-02-20 AU AU2003223184A patent/AU2003223184A1/en not_active Abandoned
- 2003-02-20 EP EP03719313A patent/EP1476179A2/en not_active Withdrawn
- 2003-02-20 IL IL16358603A patent/IL163586A0/xx unknown
- 2003-02-20 CA CA002476765A patent/CA2476765A1/en not_active Abandoned
- 2003-02-20 US US10/371,725 patent/US7202211B2/en not_active Expired - Lifetime
- 2003-02-20 JP JP2003571249A patent/JP2005518443A/ja active Pending
- 2003-02-20 WO PCT/US2003/005090 patent/WO2003072543A2/en not_active Application Discontinuation
-
2007
- 2007-02-12 US US11/705,644 patent/US20070173453A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003223184A8 (en) | 2003-09-09 |
WO2003072543A2 (en) | 2003-09-04 |
WO2003072543A3 (en) | 2004-05-21 |
US20030219430A1 (en) | 2003-11-27 |
EP1476179A2 (en) | 2004-11-17 |
IL163586A0 (en) | 2005-12-18 |
AU2003223184A1 (en) | 2003-09-09 |
US20070173453A1 (en) | 2007-07-26 |
US7202211B2 (en) | 2007-04-10 |
JP2005518443A (ja) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110306557A1 (en) | Neural regeneration peptides and methods for their use in treatment of brain damage | |
US20070173453A1 (en) | Methods of preventing or treating brain ischemia or brain injury | |
JP6000245B2 (ja) | 鎮痛作用とasicチャンネルを阻害する新規ペプチド | |
CA2516364A1 (en) | Method of modulation | |
US8138304B2 (en) | Neural regeneration peptides and formulations thereof | |
US20100040623A1 (en) | Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins | |
KR102253900B1 (ko) | 흥분성 신경독성 관련 손상 치료용 펩타이드 | |
CN112194730B (zh) | 一种多肽ti-16及其用途 | |
US6429010B1 (en) | DNA encoding the human synapsin III gene and uses thereof | |
JP2004508827A (ja) | カルシウム結合タンパク質 | |
US7749758B2 (en) | Human and mammalian stem cell-derived neuron survival factors | |
US7339039B2 (en) | Nucleic acids encoding receptor recognition factors, and methods of use thereof | |
JP4503287B2 (ja) | 星状細胞及び星状細胞性腫瘍細胞の増殖を阻害する方法と、ニューロンの生存を高める方法、並びにその使用 | |
US11571462B2 (en) | Engineered CCL20 locked dimer polypeptide | |
US20090291887A1 (en) | Proteins of the SDF-1-Family for the Manufacturing of a Medicament | |
US6291651B1 (en) | Antibodies to a novel src-family kinase | |
US20030082645A1 (en) | DNA encoding the human synapsin III gene and uses thereof | |
WO1997040155A1 (en) | Protein mediating neuronal-glial interaction, dna encoding the same, and methods of use thereof | |
US20090029456A1 (en) | STR50 and uses thereof | |
WO1998029547A1 (en) | Modulators of radial glia-astrocyte differentiation and transformation, and diagnostic and therapeutic uses thereof | |
KR20180135493A (ko) | 흥분성 신경독성 관련 손상의 치료 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |